Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells.

La Rocca F, Airoldi I, Di Carlo E, Marotta P, Falco G, Simeon V, Laurenzana I, Trino S, De Luca L, Todoerti K, Villani O, Lackmann M, D'Auria F, Frassoni F, Neri A, Del Vecchio L, Musto P, Cilloni D, Caivano A.

Cell Oncol (Dordr). 2017 Oct;40(5):483-496. doi: 10.1007/s13402-017-0338-4. Epub 2017 Jul 18.

2.

EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.

Charmsaz S, Al-Ejeh F, Yeadon TM, Miller KJ, Smith FM, Stringer BW, Moore AS, Lee FT, Cooper LT, Stylianou C, Yarranton GT, Woronicz J, Scott AM, Lackmann M, Boyd AW.

Leukemia. 2017 Aug;31(8):1779-1787. doi: 10.1038/leu.2016.371. Epub 2016 Dec 6.

PMID:
27922598
3.

An activated form of ADAM10 is tumor selective and regulates cancer stem-like cells and tumor growth.

Atapattu L, Saha N, Chheang C, Eissman MF, Xu K, Vail ME, Hii L, Llerena C, Liu Z, Horvay K, Abud HE, Kusebauch U, Moritz RL, Ding BS, Cao Z, Rafii S, Ernst M, Scott AM, Nikolov DB, Lackmann M, Janes PW.

J Exp Med. 2016 Aug 22;213(9):1741-57. doi: 10.1084/jem.20151095. Epub 2016 Aug 8.

4.

PTP-PEST controls EphA3 activation and ephrin-induced cytoskeletal remodelling.

Mansour M, Nievergall E, Gegenbauer K, Llerena C, Atapattu L, Hallé M, Tremblay ML, Janes PW, Lackmann M.

J Cell Sci. 2016 Jan 15;129(2):277-89. doi: 10.1242/jcs.174490. Epub 2015 Dec 7.

5.

The role of proteases in regulating Eph/ephrin signaling.

Atapattu L, Lackmann M, Janes PW.

Cell Adh Migr. 2014;8(4):294-307. doi: 10.4161/19336918.2014.970026. Review.

6.

A mathematical model for eph/ephrin-directed segregation of intermingled cells.

Aharon R, Janes PW, Burgess AW, Hamza K, Klebaner F, Lackmann M.

PLoS One. 2014 Dec 1;9(12):e111803. doi: 10.1371/journal.pone.0111803. eCollection 2014.

7.

Hypoxia-controlled EphA3 marks a human endometrium-derived multipotent mesenchymal stromal cell that supports vascular growth.

To C, Farnsworth RH, Vail ME, Chheang C, Gargett CE, Murone C, Llerena C, Major AT, Scott AM, Janes PW, Lackmann M.

PLoS One. 2014 Nov 24;9(11):e112106. doi: 10.1371/journal.pone.0112106. eCollection 2014.

8.

Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment.

Vail ME, Murone C, Tan A, Hii L, Abebe D, Janes PW, Lee FT, Baer M, Palath V, Bebbington C, Yarranton G, Llerena C, Garic S, Abramson D, Cartwright G, Scott AM, Lackmann M.

Cancer Res. 2014 Aug 15;74(16):4470-81. doi: 10.1158/0008-5472.CAN-14-0218.

9.

Therapeutic targeting of EPH receptors and their ligands.

Boyd AW, Bartlett PF, Lackmann M.

Nat Rev Drug Discov. 2014 Jan;13(1):39-62. doi: 10.1038/nrd4175. Review.

PMID:
24378802
10.

Vascular remodeling in cancer.

Farnsworth RH, Lackmann M, Achen MG, Stacker SA.

Oncogene. 2014 Jul 3;33(27):3496-505. doi: 10.1038/onc.2013.304. Epub 2013 Aug 5. Review.

PMID:
23912450
11.

EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme.

Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Wilson J, Ensbey KS, Jamieson PR, Bruce ZC, Lim YC, Offenhäuser C, Charmsaz S, Cooper LT, Ellacott JK, Harding A, Leveque L, Inglis P, Allan S, Walker DG, Lackmann M, Osborne G, Khanna KK, Reynolds BA, Lickliter JD, Boyd AW.

Cancer Cell. 2013 Feb 11;23(2):238-48. doi: 10.1016/j.ccr.2013.01.007.

12.

Antibodies binding the ADAM10 substrate recognition domain inhibit Eph function.

Atapattu L, Saha N, Llerena C, Vail ME, Scott AM, Nikolov DB, Lackmann M, Janes PW.

J Cell Sci. 2012 Dec 15;125(Pt 24):6084-93. doi: 10.1242/jcs.112631. Epub 2012 Oct 29.

13.

Eph/Ephrin signaling in injury and inflammation.

Coulthard MG, Morgan M, Woodruff TM, Arumugam TV, Taylor SM, Carpenter TC, Lackmann M, Boyd AW.

Am J Pathol. 2012 Nov;181(5):1493-503. doi: 10.1016/j.ajpath.2012.06.043. Epub 2012 Sep 25. Review.

14.

Targeting of EPH receptor tyrosine kinases for anticancer therapy.

Nievergall E, Saunders T, Lackmann M.

Crit Rev Oncog. 2012;17(2):211-32. Review.

PMID:
22471709
15.

Concepts and consequences of Eph receptor clustering.

Janes PW, Nievergall E, Lackmann M.

Semin Cell Dev Biol. 2012 Feb;23(1):43-50. doi: 10.1016/j.semcdb.2012.01.001. Epub 2012 Jan 12. Review.

PMID:
22261642
16.

Eph-dependent cell-cell adhesion and segregation in development and cancer.

Nievergall E, Lackmann M, Janes PW.

Cell Mol Life Sci. 2012 Jun;69(11):1813-42. doi: 10.1007/s00018-011-0900-6. Epub 2011 Dec 28. Review.

PMID:
22204021
17.

Eph receptor function is modulated by heterooligomerization of A and B type Eph receptors.

Janes PW, Griesshaber B, Atapattu L, Nievergall E, Hii LL, Mensinga A, Chheang C, Day BW, Boyd AW, Bastiaens PI, Jørgensen C, Pawson T, Lackmann M.

J Cell Biol. 2011 Dec 12;195(6):1033-45. doi: 10.1083/jcb.201104037. Epub 2011 Dec 5.

18.

PTP1B regulates Eph receptor function and trafficking.

Nievergall E, Janes PW, Stegmayer C, Vail ME, Haj FG, Teng SW, Neel BG, Bastiaens PI, Lackmann M.

J Cell Biol. 2010 Dec 13;191(6):1189-203. doi: 10.1083/jcb.201005035. Epub 2010 Dec 6.

19.

Architecture of Eph receptor clusters.

Himanen JP, Yermekbayeva L, Janes PW, Walker JR, Xu K, Atapattu L, Rajashankar KR, Mensinga A, Lackmann M, Nikolov DB, Dhe-Paganon S.

Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):10860-5. doi: 10.1073/pnas.1004148107. Epub 2010 May 26.

20.

Expression of nodal signalling components in cycling human endometrium and in endometrial cancer.

Papageorgiou I, Nicholls PK, Wang F, Lackmann M, Makanji Y, Salamonsen LA, Robertson DM, Harrison CA.

Reprod Biol Endocrinol. 2009 Oct 29;7:122. doi: 10.1186/1477-7827-7-122.

21.

Cytoplasmic relaxation of active Eph controls ephrin shedding by ADAM10.

Janes PW, Wimmer-Kleikamp SH, Frangakis AS, Treble K, Griesshaber B, Sabet O, Grabenbauer M, Ting AY, Saftig P, Bastiaens PI, Lackmann M.

PLoS Biol. 2009 Oct;7(10):e1000215. doi: 10.1371/journal.pbio.1000215. Epub 2009 Oct 13.

22.

Eph/ephrin signalling and function in oncogenesis: lessons from embryonic development.

Janes PW, Adikari S, Lackmann M.

Curr Cancer Drug Targets. 2008 Sep;8(6):473-9. Review.

PMID:
18781894
23.

Eph, a protein family coming of age: more confusion, insight, or complexity?

Lackmann M, Boyd AW.

Sci Signal. 2008 Apr 15;1(15):re2. doi: 10.1126/stke.115re2. Review.

PMID:
18413883
24.

Elevated protein tyrosine phosphatase activity provokes Eph/ephrin-facilitated adhesion of pre-B leukemia cells.

Wimmer-Kleikamp SH, Nievergall E, Gegenbauer K, Adikari S, Mansour M, Yeadon T, Boyd AW, Patani NR, Lackmann M.

Blood. 2008 Aug 1;112(3):721-32. doi: 10.1182/blood-2007-11-121681. Epub 2008 Apr 2.

25.

Crystal structure of the human ephrin-A5 ectodomain.

Nikolov D, Li C, Lackmann M, Jeffrey P, Himanen J.

Protein Sci. 2007 May;16(5):996-1000. Epub 2007 Mar 30.

26.

Eph/Ephrin membrane proteins: a mammalian expression vector pTIg-BOS-Fc allowing rapid protein purification.

Day BW, Smith FM, Chen K, McCarron JK, Herath NI, Lackmann M, Boyd AW.

Protein Pept Lett. 2006;13(2):193-6.

PMID:
16472084
27.

Adam meets Eph: an ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans.

Janes PW, Saha N, Barton WA, Kolev MV, Wimmer-Kleikamp SH, Nievergall E, Blobel CP, Himanen JP, Lackmann M, Nikolov DB.

Cell. 2005 Oct 21;123(2):291-304.

28.

Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: potential as EphA3-specific tumor-targeting reagents.

Vearing C, Lee FT, Wimmer-Kleikamp S, Spirkoska V, To C, Stylianou C, Spanevello M, Brechbiel M, Boyd AW, Scott AM, Lackmann M.

Cancer Res. 2005 Aug 1;65(15):6745-54.

29.

"Eph receptor signalling; dimerisation just isn't enough".

Vearing CJ, Lackmann M.

Growth Factors. 2005 Mar;23(1):67-76. Review. No abstract available.

PMID:
16019428
30.

Eph-modulated cell morphology, adhesion and motility in carcinogenesis.

Wimmer-Kleikamp SH, Lackmann M.

IUBMB Life. 2005 Jun;57(6):421-31. Review.

31.

Three distinct molecular surfaces in ephrin-A5 are essential for a functional interaction with EphA3.

Day B, To C, Himanen JP, Smith FM, Nikolov DB, Boyd AW, Lackmann M.

J Biol Chem. 2005 Jul 15;280(28):26526-32. Epub 2005 May 18.

32.

Repelling class discrimination: ephrin-A5 binds to and activates EphB2 receptor signaling.

Himanen JP, Chumley MJ, Lackmann M, Li C, Barton WA, Jeffrey PD, Vearing C, Geleick D, Feldheim DA, Boyd AW, Henkemeyer M, Nikolov DB.

Nat Neurosci. 2004 May;7(5):501-9. Epub 2004 Apr 25.

PMID:
15107857
33.

Recruitment of Eph receptors into signaling clusters does not require ephrin contact.

Wimmer-Kleikamp SH, Janes PW, Squire A, Bastiaens PI, Lackmann M.

J Cell Biol. 2004 Mar 1;164(5):661-6.

34.

Dissecting the EphA3/Ephrin-A5 interactions using a novel functional mutagenesis screen.

Smith FM, Vearing C, Lackmann M, Treutlein H, Himanen J, Chen K, Saul A, Nikolov D, Boyd AW.

J Biol Chem. 2004 Mar 5;279(10):9522-31. Epub 2003 Dec 2.

35.

Proapoptotic BH3-only proteins trigger membrane integration of prosurvival Bcl-w and neutralize its activity.

Wilson-Annan J, O'Reilly LA, Crawford SA, Hausmann G, Beaumont JG, Parma LP, Chen L, Lackmann M, Lithgow T, Hinds MG, Day CL, Adams JM, Huang DC.

J Cell Biol. 2003 Sep 1;162(5):877-87.

36.

The structure of Bcl-w reveals a role for the C-terminal residues in modulating biological activity.

Hinds MG, Lackmann M, Skea GL, Harrison PJ, Huang DC, Day CL.

EMBO J. 2003 Apr 1;22(7):1497-507.

37.

The role of the Eph-ephrin signalling system in the regulation of developmental patterning.

Coulthard MG, Duffy S, Down M, Evans B, Power M, Smith F, Stylianou C, Kleikamp S, Oates A, Lackmann M, Burns GF, Boyd AW.

Int J Dev Biol. 2002;46(4):375-84. Review.

38.

Ephrin-A5 induces rounding, blebbing and de-adhesion of EphA3-expressing 293T and melanoma cells by CrkII and Rho-mediated signalling.

Lawrenson ID, Wimmer-Kleikamp SH, Lock P, Schoenwaelder SM, Down M, Boyd AW, Alewood PF, Lackmann M.

J Cell Sci. 2002 Mar 1;115(Pt 5):1059-72.

39.

Crystal structure of an Eph receptor-ephrin complex.

Himanen JP, Rajashankar KR, Lackmann M, Cowan CA, Henkemeyer M, Nikolov DB.

Nature. 2001 Dec 20-27;414(6866):933-8.

PMID:
11780069
40.

Signals from Eph and ephrin proteins: a developmental tool kit.

Boyd AW, Lackmann M.

Sci STKE. 2001 Dec 11;2001(112):re20. Review.

PMID:
11741094
41.

The 3T3-L1 fibroblast to adipocyte conversion is accompanied by increased expression of angiopoietin-1, a ligand for tie2.

Stacker SA, Runting AS, Caesar C, Vitali A, Lackmann M, Chang J, Ward L, Wilks AF.

Growth Factors. 2000;18(3):177-91.

PMID:
11334054
42.

Isolation and characterization of "orphan-RTK" ligands using an integrated biosensor approach.

Lackmann M.

Methods Mol Biol. 2001;124:335-59. No abstract available.

PMID:
11100485
43.

Solution structure and mutagenesis of the caspase recruitment domain (CARD) from Apaf-1.

Day CL, Dupont C, Lackmann M, Vaux DL, Hinds MG.

Cell Death Differ. 1999 Nov;6(11):1125-32.

44.

An early developmental role for eph-ephrin interaction during vertebrate gastrulation.

Oates AC, Lackmann M, Power MA, Brennan C, Down LM, Do C, Evans B, Holder N, Boyd AW.

Mech Dev. 1999 May;83(1-2):77-94.

45.

Biomolecular interaction analysis of IFN gamma-induced signaling events in whole-cell lysates: prevalence of latent STAT1 in high-molecular weight complexes.

Lackmann M, Harpur AG, Oates AC, Mann RJ, Gabriel A, Meutermans W, Alewood PF, Kerr IM, Stark GR, Wilks AF.

Growth Factors. 1998;16(1):39-51.

PMID:
9777369
46.

Distinct subdomains of the EphA3 receptor mediate ligand binding and receptor dimerization.

Lackmann M, Oates AC, Dottori M, Smith FM, Do C, Power M, Kravets L, Boyd AW.

J Biol Chem. 1998 Aug 7;273(32):20228-37.

47.

Ligand for EPH-related kinase (LERK) 7 is the preferred high affinity ligand for the HEK receptor.

Lackmann M, Mann RJ, Kravets L, Smith FM, Bucci TA, Maxwell KF, Howlett GJ, Olsson JE, Vanden Bos T, Cerretti DP, Boyd AW.

J Biol Chem. 1997 Jun 27;272(26):16521-30.

48.

Structural determinants of the interaction between the erbB2 receptor and the Src homology 2 domain of Grb7.

Janes PW, Lackmann M, Church WB, Sanderson GM, Sutherland RL, Daly RJ.

J Biol Chem. 1997 Mar 28;272(13):8490-7.

49.

Purification of a ligand for the EPH-like receptor HEK using a biosensor-based affinity detection approach.

Lackmann M, Bucci T, Mann RJ, Kravets LA, Viney E, Smith F, Moritz RL, Carter W, Simpson RJ, Nicola NA, Mackwell K, Nice EC, Wilks AF, Boyd AW.

Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2523-7.

50.

S100 protein CP-10 stimulates myeloid cell chemotaxis without activation.

Cornish CJ, Devery JM, Poronnik P, Lackmann M, Cook DI, Geczy CL.

J Cell Physiol. 1996 Feb;166(2):427-37.

PMID:
8592003

Supplemental Content

Loading ...
Support Center